Company Description
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 7, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Neal Walker |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 324 7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer and Director |
| Kevin Balthaser | Chief Financial Officer |
| Dr. Roland Kolbeck Ph.D. | Chief Scientific Officer |
| William C. Roberts | Senior Vice President of Corporate Communications and Investor Relations |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| James Loerop | Chief Business Officer |
| Steve Tucker | Executive Vice President of Project Leadership |
| Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | SCHEDULE 13G/A | Filing |
| Jan 6, 2026 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |